Clinical Trial Update: Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders [Phase 2]

View source ↗

Summary

Phase 2 trial update for SJP-0035 ophthalmic solution in corneal epithelial disorders completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Epithelial Disorders

Drugs mentioned

• SJP-0035 (unknown)

Snippet

Sponsor: Senju Pharmaceutical Co., Ltd. | Conditions: Corneal Epithelial Disorders | Phase 2 | Status: COMPLETED